Physician profile
Gitanjali B Baveja
NPI 1164563946
$4,053.41
in general payments reported to CMS, 2019-2025
18 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,011 · 2020: $139 · 2021: $209 · 2022: $630 · 2023: $994 · 2024: $970 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,300.43 | 2019-2023 | Veritas Vision System, Tecnis Iol, Star S4 Ir |
| Abbvie INC. | $1,230.06 | 2022-2025 | Lumigan, Vuity, Durysta |
| Alcon Vision LLC | $324.00 | 2019-2022 | |
| Biotissue Holdings INC. | $253.96 | 2024 | |
| Sun Pharmaceutical Industries INC. | $134.72 | 2020-2023 | Cequa |
| Dompe US, INC. | $130.10 | 2021-2024 | Oxervate |
| Astellas Pharma US INC | $104.73 | 2023 | |
| Janssen Global Services, LLC | $95.79 | 2024 | |
| Allergan, INC. | $94.97 | 2021-2022 | |
| Rxsight INC | $65.63 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $64.53 | 2022-2025 | Xiidra, Miebo, Alden Scleral Zenlens |
| Kala Pharmaceuticals, INC. | $55.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $53.39 | 2021-2023 | |
| Glaukos Corporation | $40.87 | 2024-2025 | Ce-Marked Kxla System, Photrexa Viscous and Photrexa |
| Oyster Point Pharma, INC. | $37.19 | 2022-2024 | Tyrvaya |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $25.39 | 2024 | Vevye |
| Amgen INC. | $21.14 | 2024 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $21.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gitanjali Baveja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.